DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Phase 3

Terminated

Conditions: Non Squamous, Non-small-cell Lung Cancer

Interventions: Drug: Placebo
Drug: Tivantinib
Drug: Erlotinib

First Posted Date: 2010-11-19

Last Posted Date: 2021-04-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1048

Registration Number: NCT01244191

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: PLX3397

First Posted Date: 2010-10-08

Last Posted Date: 2020-06-30

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 20

Registration Number: NCT01217229

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: U3-1287
Drug: Placebo
Drug: Erlotinib

First Posted Date: 2010-09-29

Last Posted Date: 2021-06-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 222

Registration Number: NCT01211483

Locations: 🇺🇸
TRM - Oncology Research Associates, PLLC, d/b/a Pinnacle Oncology Hematology, Scottsdale, Arizona, United States

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Tivantinib (ARQ 197) Capsule
Drug: Tivantinib (ARQ 197) Tablet
Drug: Tivantinib (ARQ 197) Capsule D, oral

First Posted Date: 2010-06-23

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT01149720

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States

and more 1 locations

Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: CS-1008
Drug: FOLFIRI

First Posted Date: 2010-05-17

Last Posted Date: 2013-12-03

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 21

Registration Number: NCT01124630

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: CS-7017
Drug: erlotinib

First Posted Date: 2010-04-09

Last Posted Date: 2020-06-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 90

Registration Number: NCT01101334

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Hwasun Hospital, Jeonnam, Korea, Republic of
🇮🇳
Apollo Speciality Hospital, Chennai, Tamil Nadu, India

and more 14 locations

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Placebo
Drug: Tivantinib
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2010-02-24

Last Posted Date: 2021-04-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 131

Registration Number: NCT01075048

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Phase 2

Terminated

Conditions: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)

Interventions: Drug: Tivantinib (ARQ 197)

First Posted Date: 2010-01-25

Last Posted Date: 2021-04-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 27

Registration Number: NCT01055067

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Compound AC220

First Posted Date: 2010-01-15

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 45

Registration Number: NCT01049893

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Phase 2

Completed

Conditions: Advanced Hepatocellular Carcinoma
Liver Cancer
Hepatic Cancer
Liver Neoplasms

Interventions: Drug: CS-1008 2 mg/kg
Drug: Sorafenib
Drug: CS-1008 4 mg/kg
Drug: CS-1008 6 mg/kg
Drug: CS-1008 6/2 mg/kg
Drug: CS-1008 6/6 mg/kg

First Posted Date: 2009-12-16

Last Posted Date: 2021-04-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 172

Registration Number: NCT01033240

Locations: 🇺🇸
Kenmar Research Group, Los Angeles, California, United States
🇯🇵
Hiroshima University, Hiroshima-city, Hiroshima, Japan
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 25 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy